atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase...

Tue, Oct 21

Perspectives

RT @C_Angermayer: It feels as if Santa came early this year: Outstanding data for BPL-003, an FDA Breakthrough Therapy Designation as a re…

Cash, cash equivalents, short-term investments and other liquid assets expected to fund operations into 2029, beyond anticipated top-line results from the first Phase 3 clinical trial of BPL-003 NEW...

Discover